About Rejuvenate Bio
Rejuvenate Bio is a Healthcare company based in San Diego (United States) founded in 2017 by Noah Davidsohn, George Church, and Daniel Oliver. Gene-editing platform and anti-aging therapy for dogs are developed. Rejuvenate Bio has raised $34.05 million across 3 funding rounds from investors including KdT Ventures, Digitalis Ventures and VCapital. The company has 39 employees. Its chief executive, as recorded, is Daniel Oliver. Rejuvenate Bio offers products and services including Gene Therapy Pipeline. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Genomics. Its legal entity is REJUVENATE BIO INC. Its competitors include Beam Therapeutics, eGenesis and Korro Bio; 3 of its 3 listed competitors have raised funding.
Company details
Rejuvenate Bio was founded in 2017 and is based in San Diego, United States. A gene-editing platform is developed by the company for anti-aging therapies targeting dogs. Technology has been applied to modulate gene activity in aged mice. Plans are in place to modify two genes addressing four aging-related diseases: heart and kidney failure, obesity, and diabetes. Operations focus on biotechnology within the veterinary and longevity sectors.
- Headquarters San Diego, United States
- Employees 39
- Founders Noah Davidsohn, George Church, Daniel Oliver
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website rejuvenatebio.com
- Social LinkedIn X Facebook
- Legal Name Rejuvenate Bio Inc.
- Total Equity Funding$34.05M (USD)
in 3 rounds
- Latest Funding Round$19.47M (USD), Series A
Jun 2026
- InvestorsKdT Ventures
& 7 more
- Employee Count39
Products & Services of Rejuvenate Bio
Rejuvenate Bio offers a comprehensive portfolio of products and services, including Gene Therapy Pipeline.
Develops treatments for chronic diseases via gene therapy approaches
Funding Insights of Rejuvenate Bio
Rejuvenate Bio has successfully raised a total of $34.05M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $19.47 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $34.05M
- Total Rounds 3
- Last Round Series A — $19.47M
- First Round $14.58M
(Apr 2021)
- Investors Count 8
All 3 funding rounds of Rejuvenate Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2026 | $19.47M | Series A | – | VCapital | |
| Jul 2024 | $4M | Grant | – | – | |
| Apr 2021 | $14.58M | Series A | – | KdT Ventures, Digitalis Ventures |
8 investors in total: 7 institutional and 1 angel.
Investors in Rejuvenate Bio
Rejuvenate Bio has secured backing from 8 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include KdT Ventures, Digitalis Ventures and VCapital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments are made in frontier science ventures. | kdtvc.com | Black Mountain, United States | ||
Digitalis Ventures is engaged in health-focused investments. | digitalisventures.com | New York, United States | ||
Venture capital investment opportunities are provided for accredited investors. | vcapital.com | |||
Venture capital investments are focused on health technology breakthroughs. | kcpventures.com | Boston, United States | ||
| ctinnovations.com | ||||
| cirm.ca.gov | ||||
| merck-animal-health.com | ||||
KH Katherine High | Biotech pioneer, angel investor, and gene therapy expert based in India. | unknown_2e7383ffe478452b9 |
Investor details for Rejuvenate Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Rejuvenate Bio
11 people are tracked at Rejuvenate Bio (4 in leadership, 7 in board & advisors); the tracked headcount is 39.
| Name | Role | Group |
|---|---|---|
Noah Davidsohn | Co-Founder & CSO | Leadership |
George Church | Co-Founder & SAB | Leadership |
Daniel Oliver | Co-Founder & CEO | Leadership |
Deborah Ascheim | Chief Medical Officer | Leadership |
Vicky Yang | Scientific Advisor | Board & advisors |
Fabian Kausche | Scientific Advisor | Board & advisors |
Katherine High | Scientific Advisor | Board & advisors |
Hugh Calkins | Scientific Advisor | Board & advisors |
Elif Oral | Scientific Advisor | Board & advisors |
Frank Greenway | Scientific Advisor | Board & advisors |
Stephen Chelko | Scientific Advisor | Board & advisors |
Complete people profiles for Rejuvenate Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Rejuvenate Bio
3 dated milestones of Rejuvenate Bio across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Rejuvenate Bio is founded.
- Funding First funding round of $14.6M.
- Funding Latest funding round, Series A, of $19.5M.
Competitors of Rejuvenate Bio
Rejuvenate Bio has 3 listed competitors in our database, 3 of them funded. They include Beam Therapeutics, eGenesis and Korro Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beamtx.com | 2017 | Cambridge, United States | $222M | 340 | Developer of gene therapy using CRISPR base editing to treat diseases | |
| egenesisbio.com | 2015 | Cambridge, United States | $481.42M | 94 | Gene transplantation platform for humanizing pig cells is developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. |
Detailed competitors of Rejuvenate Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Rejuvenate Bio
The website of Rejuvenate Bio (rejuvenatebio.com) receives about 3.6K visits a month and ranks #6,705,306 among all websites worldwide, #6,713 in Biotechnology and Pharmaceuticals.
- Monthly visits3.6K
▲ 53.5% vs previous month
- Unique visitors1K
per month
- Global rank#6,705,306
among all websites
- Category rank#6,713
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.7
- Average visit1 min 19 sec
- DevicesDesktop 46% · Mobile 54%
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Rejuvenate Bio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rejuvenate Bio
Complete news archive for Rejuvenate Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rejuvenate Bio
Rejuvenate Bio was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Rejuvenate Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Daniel Oliver is the CEO of Rejuvenate Bio, as recorded in our data. They have also founded this company.
Rejuvenate Bio is a funded company, having raised a total of $34.05M across 3 funding rounds to date. The company's 1st funding round was a Series A of $14.58M, raised on Apr 2021.
Rejuvenate Bio has 39 employees.
Rejuvenate Bio was founded in 2017 and is based in San Diego, United States. A gene-editing platform is developed by the company for anti-aging therapies targeting dogs. Technology has been applied to modulate gene activity in aged mice. Plans are in place to modify two genes addressing four aging-related diseases: heart and kidney failure, obesity, and diabetes. Operations focus on biotechnology within the veterinary and longevity sectors.
Rejuvenate Bio's top competitors include eGenesis, Korro Bio and Beam Therapeutics.
Rejuvenate Bio offers Gene Therapy Pipeline.
Rejuvenate Bio has 8 investors. Key investors include KdT Ventures, Digitalis Ventures, VCapital, Katherine High, and Kendall Capital Partners.
Rejuvenate Bio operates through Rejuvenate Bio Inc..